SS-31
SS-31 (also studied under the name elamipretide) is supplied as a mitochondria-targeted peptide for cardiolipin-binding and mitochondrial-bioenergetics pathway research. Supplied strictly for laboratory and educational research. Not for human or veterinary use.
Vial amount
Purchase option
Checkout includes a research-use attestation. Materials are supplied only for laboratory and educational research.
SS-31 in research
SS-31 (also studied under the name elamipretide) is supplied as a mitochondria-targeted peptide for cardiolipin-binding and mitochondrial-bioenergetics pathway research.
Mitochondrial, redox, and energy-pathway research for documented lab work.
Bench context
Supplied as a research-grade reference material for documented laboratory and educational research workflows.
Available amounts
Select from the stocked vial amounts for SS-31 before adding the material to cart.
Claims discipline
No protocol instructions, no dosing, no medical advice, and no therapeutic or human-use promises.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, not for diagnostic or therapeutic use, not a drug or supplement.
As listed by the supplier in BioRegen's ordering system, shown here exactly as written for transparency. This is the vendor's own description, not independently verified, edited, or endorsed by BioRegen, and is not a BioRegen claim of any effect.
10mg
Disclaimer: All products on this site are for Research and Development use only. Products are Not for Human Consumption of any kind. The statements made within this website have not been evaluated by the U.S. Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure, or prevent any disease.
Ss-31 is a groundbreaking peptide that is making waves in the field of mitochondrial research. Mitochondria, often referred to as the powerhouses of the cell, play a crucial role in energy production and overall cellular health. Ss-31 is uniquely designed to target and stabilize these vital organelles, potentially supporting their function and efficiency.
Research into Ss-31 has shown promising results, with studies indicating its ability to enhance mitochondrial performance, which may lead to improved energy production at the cellular level. This peptide's capacity to penetrate cell membranes efficiently and localize within mitochondria sets it apart, offering a novel approach to studying energy dynamics within cells.
With ongoing research, Ss-31 continues to capture the interest of scientists aiming to unlock new insights into cellular bioenergetics and the role of mitochondria in health and disease. Its potential to aid in understanding complex biological processes makes it an indispensable tool for researchers dedicated to advancing the frontiers of life sciences.
The full research picture, clearly labeled
BioRegen reports the entire research landscape for this compound across four clearly separated tiers, strongest evidence first. Lower tiers, including community and anecdotal reports, are labeled as such and are not BioRegen claims.
SS-31, known in investigational settings as elamipretide, has been studied in human clinical trials for primary mitochondrial diseases and other mitochondrial-dysfunction conditions, with mixed outcomes reported by investigators.
SS-31 concentrates at the inner mitochondrial membrane and binds cardiolipin; preclinical work links this interaction to cristae structure and bioenergetics in mitochondrial models.
SS-31 is discussed in longevity and mitochondrial-health communities. That discussion is unverified anecdotal commentary, not controlled data, and not a BioRegen claim.
Investigational (elamipretide); not FDA-approved. BioRegen supplies SS-31 reference material strictly for laboratory and educational research, not for human use.
Tiers are evidence categories, not endorsements. Clinical and preclinical entries summarize third-party published research. Community and anecdotal entries are unverified reports discussed by others, not findings and not BioRegen claims. Nothing here is medical advice, and no compound is approved for human or veterinary use except where explicitly stated under Regulatory status.
What the published research says about SS-31
This section reports on published research referenced in BioRegen's own research library. It is not a claim by BioRegen that the compound provides any benefit, and nothing here is medical advice.
- Birk AV, et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol. 2013. https://doi.org/10.1681/ASN.2012121216
- Chavez JD, et al. Mitochondrial protein interaction landscape of SS-31. Proc Natl Acad Sci U S A. 2020. https://doi.org/10.1073/pnas.2002250117